Author/Editor     Čufer, Tanja
Title     Dopolnilno sistemsko zdravljenje raka dojk
Translated title     Adjuvant systemic treatment of breast cancer
Type     članek
Source     In: Takač I, Arko D, editors. 30 let Centra za bolezni dojk v Mariboru. Zbornik predavanj Simpozij z mednarodno udeležbo; 2003 maj 23; Maribor. Maribor: Splošna bolnišnica Maribor,
Publication year     2003
Volume     str. 85-95
Language     slo
Abstract     In breast cancer, the efficacy of systemic treatment was first established in patients with disseminated disease. In view of this it was presumed that systemic treatment would also affect micrometastases which were present in primary treatment and prevent later dissemination of the disease. This was confirmed by numerous individual studies and metaanalyses. Adjuvant hormone treatment decreases mortality due to breast cancer by 47%, adjuvant cytostatic treatment by 27%. Hormone therapy is effective in all patients with hormone-dependent disease. Today, standard adjuvant hormone therapy of pre- as well as postmenopausal women is treatment with the antiestrogen tamoxifen. In premenopausal patients not receiving cytostatic therapy or in those with normal menstrual cycle following such treatment, it would be advisable to supplement ovariectomy by tamoxifen therapy. Cytostatic treatment decreases the risk of recurrence and mortality in all patients. However, its benefit is greater in patients with poorer prognosis, in younger patients and in those with hormone-independent cancer. Anthracycline containing regimens are more effective than nonanthracycline regimens. For adjuvant treatment, newer and more effective drugs such as taxanes, selective antiestrogens, new aromatase inhibitors, monoclonal antibodies and others are being studied with the aim of additional improvement of adjuvant systemic breast cancer treatment in the future. Particularly significant and encouraging is the search for new factors predicting the therapeutic response, molecular markers on the basis of which the corresponding patient selection would be carried out.
Descriptors     BREAST NEOPLASMS
CHEMOTHERAPY, ADJUVANT